Flexeril, also known by its generic name cyclobenzaprine, is a muscle relaxant often prescribed to treat muscle spasms associated with painful musculoskeletal conditions like fibromyalgia or spinal cord injuries. It's one of the most commonly used medications for these conditions and has a long history of helping many people manage their pain.
Flexeril (cyclobenzaprine) is a muscle relaxant. It works by blocking pain signals that are sent to your brain. Flexeril is used together with rest and physical therapy to treat skeletal muscle conditions such as pain or injury. Flexeril may also be used for purposes not listed in this medication guide. You should not take Flexeril if you have recently had a heart attack, or if you have certain heart rhythm disorders. Do not use Flexeril if you have taken an MAO inhibitor in the past 14 days, such as isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, tranylcypromine, and others.
Flexeril works by inhibiting the reuptake of the neurotransmitter norepinephrine in the brain. This action results in a decrease in muscle spasms and pain. It is thought to work by affecting the transmission of signals between nerve cells in the brain. Flexeril is used to treat muscle spasms and pain associated with conditions such as multiple sclerosis, cerebral palsy, and spinal cord injuries.
The usual adult dose of Flexeril is 5 mg three times daily. The maximum recommended dose is 20 mg per day. Flexeril should be taken with food or milk to decrease stomach upset. Flexeril may interact with other medications such as antidepressants, blood pressure medications, and seizure medications.
Flexeril is a muscle relaxant that is commonly used to treat spasms, strains, and other conditions that cause muscle pain. It is also sometimes used to treat migraines and other types of headaches. Flexeril works by blocking certain nerve signals that are responsible for causing muscle pain. This can help to reduce pain and inflammation in the muscles. Flexeril is available in both oral and injectable forms. The oral form is usually taken three times a day, while the injectable form is usually given once a day. Flexeril can cause side effects such as drowsiness, dizziness, and nausea. These side effects are typically mild and go away on their own after a few days of treatment.
Flexeril has been a trusted muscle relaxant for decades and is a great option for treating skeletal muscle spasms. Medical professionals should always be aware of the potential side effects, interactions, and uses of this drug in order to provide their patients with safe and effective care. With this article as your guide, you now have all the information you need to make informed decisions about Flexeril prescriptions.
1.
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk
2.
Year in Review: Multiple Myeloma
3.
Cancer research in the US is world class. With the government pulling out, its future is uncertain
4.
Beyond What Is Visible in Myelofibrosis?
5.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
1.
Best Clinical Practices in Hematology
2.
The Growing Challenge of Haematological Malignancies in Older Adults
3.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
4.
Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends
5.
Geriatric Oncology and Treatment Sequencing: Evidence-Based Approaches for the Aging Cancer Population
1.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Symposium on Oncology, Cardiology and Critical Care Innovations
4.
International Conference on Cancer Nursing and Hematology Support
5.
International Conference on Clinical Medicine and Surgical Care
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation